Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
0.9834
-0.0766 (-7.23%)
Mar 31, 2025, 1:30 PM EDT - Market open
Pyxis Oncology Employees
Pyxis Oncology had 44 employees as of December 31, 2024. The number of employees decreased by 6 or -12.00% compared to the previous year.
Employees
44
Change (1Y)
-6
Growth (1Y)
-12.00%
Revenue / Employee
$366,955
Profits / Employee
-$1,757,523
Market Cap
60.57M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44 | -6 | -12.00% |
| Dec 31, 2023 | 50 | -25 | -33.33% |
| Dec 31, 2022 | 75 | 19 | 33.93% |
| Dec 31, 2021 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PYXS News
- 5 days ago - Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - GlobeNewsWire
- 13 days ago - Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - GlobeNewsWire
- 7 weeks ago - Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial - GlobeNewsWire
- 3 months ago - Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 - GlobeNewsWire
- 4 months ago - Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead - Seeking Alpha
- 4 months ago - Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns - Benzinga